Novel triple-helical polypeptides with no binding affinity to immunoglobulin Fc domains and uses of said polypeptides
Novel triple helical polypeptides with no Fc domain binding address the interference issue in protein purification, enabling efficient and target-specific capture for therapeutic and diagnostic applications.
Patent Information
- Application Number
- JP2021519170
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-04-03
- Filing Date
- 2019-11-12
- Publication Date
- 2024-11-28
- Estimated Expiration
- 2039-11-12
AI Technical Summary
Current methods for protein purification, particularly through affinity chromatography, face challenges in achieving efficient and target-specific purification due to the interference caused by the binding of polypeptides to immunoglobulin Fc domains, limiting the development of advanced tools for therapeutic and diagnostic applications.
Development of novel polypeptides with a triple helical structure that lack binding affinity for immunoglobulin Fc domains, enabling Fc-independent purification and the creation of libraries for highly selective target-specific molecules.
These non-Fc-binding polypeptides facilitate precise capture in affinity chromatography, allowing for the identification of valuable molecules useful in therapeutics and diagnostics, and enhance the efficiency and specificity of protein purification processes.
Smart Images

Figure 0007591284000003 
Figure 0007591284000004 
Figure 0007591284000005
Abstract
Description
[Technical field]
[0001] The present invention relates to the fields of protein engineering and protein purification, in particular to novel polypeptides having a triple helical structure and no binding affinity to immunoglobulin Fc domains. The present invention further relates to the use of said novel non-Fc binding polypeptides in technical applications such as affinity chromatography, as well as in therapy and diagnosis. The present invention also relates to a method for reducing the binding affinity of a polypeptide having a triple helical structure to an immunoglobulin Fc domain. [Background technology]
[0002] Downstream processing of recombinantly produced polypeptides generally involves the purification of the polypeptides expressed in host cells. This purification process typically involves one or more chromatography steps, with affinity chromatography often used as a capture step. Although affinity chromatography is a simple and robust method that provides a pure and concentrated product in a single step, advanced tools that allow efficient and target-specific protein purification are currently needed, as well as the development of new molecules suitable for technical applications such as affinity chromatography or for use in therapy and diagnostics.
[0003] The present invention meets this need by providing novel polypeptides that have a triple helical structure and have no binding affinity for immunoglobulin Fc domains. These novel polypeptides are particularly advantageous because they allow accurate capture in affinity chromatography, resulting in non-Fc-dependent purification of proteins. Furthermore, these novel triple helical polypeptides that have no binding affinity for immunoglobulin Fc domains allow the creation of libraries that allow the identification of highly selective target-specific molecules that are useful for therapeutic and diagnostic as well as technical applications. This overview is merely illustrative and therefore does not necessarily describe all the problems solved by the present invention. Summary of the Invention
[0004] The present disclosure provides the following items 1 to 15, but is not limited to these items.
[0005] 1. A polypeptide having a triple helix structure, wherein helix 1, helix 2, and helix 3 correspond to positions 7 to 19, positions 23 to 37, and positions 40 to 56 of SEQ ID NO: 1, respectively, and the polypeptide (a) comprising an acidic amino acid selected from aspartic acid (D) and glutamic acid (E) at a position corresponding to position 13 of SEQ ID NO:1; and (b) comprising a basic amino acid selected from any one of arginine (R), lysine (K), and histidine (H) at a position corresponding to position 31 of SEQ ID NO:1; The polypeptide.
[0006] 2. The polypeptide having a triple helix structure according to item 1, wherein the polypeptide has no detectable binding affinity for an immunoglobulin Fc domain as measured by surface plasmon resonance (SPR).
[0007] 3. The polypeptide (a) containing an aspartic acid (D) at a position corresponding to position 13 of SEQ ID NO:1; and / or (b) containing an arginine (R) at a position corresponding to position 31 of SEQ ID NO:1; 3. A polypeptide having a triple helix structure according to item 1 or 2.
[0008] 4. A polypeptide having a triple helix structure according to any one of items 1 to 3, further comprising serine (S) at one or more positions corresponding to positions 10, 14, and 35 of SEQ ID NO:1.
[0009] 5. A fusion protein comprising the polypeptide according to any one of items 1 to 4.
[0010] 6. A method for producing a polypeptide having a triple helix structure according to any one of items 1 to 4, which has binding affinity for a target protein, comprising: (a) providing one or more polypeptides according to any one of items 1 to 4; (b) contacting a target protein with one or more polypeptides of (a); (c) identifying a complex containing the polypeptide according to any one of items 1 to 4 bound to the target protein; (d) obtaining a polypeptide according to any one of items 1 to 4 that is capable of binding to the target protein; A method comprising:
[0011] 7. A composition comprising a polypeptide having binding affinity for a target protein, the polypeptide being obtained by the polypeptide according to any one of items 1 to 4, or the fusion protein according to item 5, or the method according to item 6.
[0012] 8. A polypeptide having binding affinity for a target protein, obtained by a polypeptide according to any one of items 1 to 4, or a fusion protein according to item 5, or a method according to item 6, for use in a technical application.
[0013] 9. A polypeptide having binding affinity for a target protein, which is obtained by the polypeptide according to any one of items 1 to 4, or the fusion protein according to item 5, or the method according to item 6, for use in affinity chromatography.
[0014] 10. A polypeptide having binding affinity for a target protein, obtained by the method according to item 6, or the composition according to item 7, wherein the polypeptide is used as a pharmaceutical, diagnostic agent, and / or prognostic agent.
[0015] 11. A method for reducing the binding affinity of a polypeptide having a triple helix structure to an immunoglobulin Fc domain, comprising: (a) selecting at least two amino acid positions within helix 1 and helix 2 for mutagenesis, with helix 1 and helix 2 corresponding in terms of position to positions 7-19 and positions 23-37 of SEQ ID NO:1, respectively, wherein positions corresponding to positions 13 and position 31 in the amino acid sequence of SEQ ID NO:1 are selected as the at least two amino acid positions for mutagenesis; and (b) performing a mutagenesis on the at least two amino acid positions selected for mutagenesis, the mutagenesis including substituting an amino acid at a position corresponding to position 13 of SEQ ID NO:1 with an acidic amino acid selected from aspartic acid (D) and glutamic acid (E) and substituting an amino acid at a position corresponding to position 31 of SEQ ID NO:1 with a basic amino acid selected from any one of arginine (R), lysine (K), and histidine (H). A method comprising:
[0016] 12. The method according to item 11, wherein the mutation comprises substituting the amino acid at the position corresponding to position 13 of SEQ ID NO:1 with aspartic acid (D) and substituting the amino acid at the position corresponding to position 31 of SEQ ID NO:1 with arginine (R).
[0017] 13. The method according to item 11 or 12, wherein the mutation further comprises substituting one or more of the amino acids at positions corresponding to positions 10, 14, and 35 in the amino acid sequence of SEQ ID NO:1 with serine (S).
[0018] 14. A polypeptide having a triple helix structure obtainable, obtained, or prepared by the method according to any one of items 6 and 11 to 13.
[0019] 15. A polynucleotide encoding the polypeptide according to any one of items 1 to 4 and 14, or the fusion protein according to item 5.
[0020] The summary of the invention is not limiting and other aspects and embodiments of the invention will become apparent from the following description, examples, and drawings. [Brief description of the drawings]
[0021] [Figure 1] Figure 1 shows the polypeptide of SEQ ID NO: 9, which has no binding affinity to immunoglobulin Fc regions, in particular to the IgG1 Fc region. Analysis by label-free interaction assay using SPR spectroscopy (BIAcore). Solid line = Fc binding protein (SEQ ID NO: 17); dashed line = polypeptide of SEQ ID NO: 9. The change in refractive index was measured in real time and plotted as response units or resonance units [RU] against time [sec]. [Diagram 2] Figure 2 shows polypeptides of SEQ ID NO: 1, 2, 3, 5, 7 (dashed lines) that have no binding affinity to immunoglobulin Fc regions, in particular IgG1 Fc regions, compared to the Fc binding protein of SEQ ID NO: 16 (solid line). Analysis by label-free interaction assay using SPR spectroscopy (BIAcore). All concentrations = 1 μM. The change in refractive index was measured in real time and plotted as response units or resonance units [RU] against time [sec]. [Diagram 3] Figure 3 shows polypeptides of SEQ ID NO: 1, 2, 3, 5, 7 (dashed lines) that have no binding affinity to immunoglobulin Fc regions, in particular IgG1 Fc regions, compared to the Ig binding protein of SEQ ID NO: 16 or wild type Protein A Domain C or Domain A or Domain Z. Analysis by label-free interaction assay using SPR spectroscopy (BIAcore). All concentrations = 10 μM. The change in refractive index was measured in real time and plotted as response units or resonance units [RU] against time [sec]. [Figure 4]Figure 4 shows the improvement in yield after affinity chromatography of fusion proteins of SEQ ID NO:1 (non-Fc binding protein) fused to Protein A derivatives with specific target binding properties (BP). The recovery of these binding or fusion proteins was quantified by sandwich immunoassay according to the manufacturer's instructions. BP1 is binding protein 1 with Cys and His10, BP2 is binding protein 2 with Cys and His10, BP3 is binding protein 2 with Cys and His10, fusion 1 is SEQ ID NO:1-BP2-SEQ ID NO:1, fusion 2 is SEQ ID NO:1-BP1, fusion 3 is BP1-SEQ ID NO:1, fusion 4 is SEQ ID NO:1-BP3 and fusion 5 is BP3-SEQ ID NO:1. The recovery shows the relationship of the measured signal to the internal standard. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0022] The present invention provides a novel polypeptide having a triple helical structure that has no detectable binding affinity to immunoglobulin Fc domains, such as measured by surface plasmon resonance (SPR). The polypeptide of the present invention is an advanced and powerful tool that fills a gap in the fields of protein engineering and protein purification. In particular, the novel polypeptide has an advantageous effect on protein purification by changing the binding affinity to the immunoglobulin Fc region. Specifically, compared to known Ig-binding proteins, the novel polypeptide provided by the present invention allows Fc fusion proteins or antibodies themselves to be used as target proteins without interference from the Fc domain. Thus, the novel polypeptide of the present invention is particularly advantageous because it allows accurate capture in affinity chromatography by non-Fc-dependent purification of target proteins. This lack of detectable binding affinity (as measured by SPR) to an immunoglobulin Fc domain can be achieved when the polypeptide having a triple helical structure contains an acidic amino acid selected from aspartic acid (D) and glutamic acid (E) in helix 1 at a position corresponding to position 13 of SEQ ID NO: 1, and a basic amino acid selected from any one of arginine (R), lysine (K), and histidine (H) in helix 2 at a position corresponding to position 31 of SEQ ID NO: 1, where helix 1, helix 2, and helix 3 correspond, with respect to their positions, to positions 7-19, positions 23-37, and positions 40-56 of SEQ ID NO: 1, respectively.
[0023] The novel polypeptides of the invention not only allow for particularly efficient and target-specific protein purification, but also allow the identification of new valuable molecules based on new library design concepts. In particular, these novel non-Fc binding polypeptides with triple helical structure allow the creation of libraries that allow the identification of highly selective target-specific molecules that are useful not only for technical applications but also for therapeutics and diagnostics. The non-Fc binding polypeptides of the invention allow new library designs, which are based on specific amino acid substitutions identified by the inventors, and which clearly open up experimental options and may increase the success rate of selection strategies designed to identify binding proteins. For example, such libraries can be applied to target proteins fused with Fc domains in selection and screening methods, since the library scaffolds do not have detectable Fc binding affinity as measured by appropriate methods, such as SPR, resulting in fewer false positive hits for the Fc portion. In effect, this creates a wider set of novel target-specific binding molecules, each with altered target specificity, yet further characterized by not having detectable Fc binding affinity as measured by appropriate methods, such as SPR.
[0024] Before describing the invention in further detail, it should be understood that the invention is not limited to the specific methodology, protocols, and reagents described herein, which may vary. It should also be understood that the terminology used herein is merely intended to describe certain aspects and embodiments, and is not intended to limit the scope of the invention, which is reflected by the appended claims. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which the invention belongs. This includes those skilled in the art of protein engineering and protein purification, but also those skilled in the art of technical applications such as affinity chromatography, and the development of novel target-specific binding molecules for use in therapy and diagnosis.
[0025] The terms used herein are preferably defined as set forth in "A multilingual glossary of biotechnological terms: (IUPAC Recommendations)", Leuenberger, HGW, Nagel, B. and Kolbl, H., eds. (1995), Helvetica Chimica Acta, CH-4010 Basel, Switzerland.
[0026] Throughout this specification and the claims which follow, unless the context otherwise requires, the word "comprise" and variations thereof, such as "comprises" and "comprising", are understood to mean the inclusion of a stated integer or step or group of integers or steps, but not the exclusion of any other integer or step or group of integers or steps. The term "comprise(s)" or "comprising" encompasses the limitation "consists of" or "consisting of" wherever such limitation is necessary for any reason and to whatever extent.
[0027] Several documents (e.g., patents, patent applications, scientific papers, manufacturer's specifications, instructions, GenBank sequence entry accession numbers, etc.) may be cited throughout this application. Nothing herein should be construed as an admission that the date of the present invention is not entitled to antedate such disclosure by virtue of prior invention. Some of the documents cited herein may be said to be "incorporated by reference." In the event of a conflict between a definition or teaching of such an incorporated reference and a definition or teaching recited herein, the language of this application shall control.
[0028] All sequences referenced herein are disclosed in the accompanying Sequence Listing, which is incorporated herein by reference in its entirety and by its disclosure into the disclosure of this application.
[0029] General definitions of important terms used in this application The terms "protein" and "polypeptide" refer to any chain of two or more amino acids linked by peptide bonds, and do not refer to a specific length of the product. Thus, "peptide," "protein," "amino acid chain," or any other term used to refer to a chain of two or more amino acids, are included within the definition of "polypeptide," and the term "polypeptide" may be used in place of or interchangeably with any of these terms. The term "polypeptide" is also intended to refer to post-translation modification products of polypeptides that are well known in the art, such as, for example, glycosylation.
[0030] The term "triple helix structure" or "triple helix structure" refers to a polypeptide having a triple helix bundle, said polypeptide comprising at least 48 amino acids, preferably at least 50 amino acids, more preferably at least 58 amino acids, and even more preferably 58 amino acids, with helix 1 comprising amino acid residues 7-19, helix 2 comprising amino acid residues 23-37, and helix 3 comprising amino acid residues 40-56. Specifically, helix 1, helix 2, and helix 3 essentially correspond in terms of their positions to positions 7-19, positions 23-37, and positions 40-56, respectively, of SEQ ID NO: 1. In various embodiments, the present polypeptide having a triple helix structure is composed of 56 amino acids, 57 amino acids, or 58 amino acids, preferably composed of 58 amino acids.
[0031] Thus, the polypeptide provided by the present invention comprises three helical structures, with helix 1, helix 2, and helix 3 comprising the following amino acid positions relative to the amino acid positions of the sequence of SEQ ID NO: 1: that is, helix 1 is essentially at amino acid positions corresponding to positions 7-19 of the amino acid sequence of SEQ ID NO: 1, helix 2 is essentially at amino acid positions corresponding to positions 23-37 of the amino acid sequence of SEQ ID NO: 1, and helix 3 is essentially at amino acid positions corresponding to positions 40-56 of the amino acid sequence of SEQ ID NO: 1. The present specification further discloses an embodiment of a polypeptide having a triple helical structure provided by the present invention, in which helix 1 corresponds essentially to positions 6-19 of the amino acid sequence of SEQ ID NO: 1, helix 2 corresponds essentially to positions 23-37 of the amino acid sequence of SEQ ID NO: 1, and helix 3 corresponds essentially to positions 40-56 of the amino acid sequence of SEQ ID NO: 1.
[0032] As disclosed herein, the polypeptides of the invention having a triple helical structure may also be described as folded polypeptides having a triple helical structure. As further disclosed herein, the polypeptides of the invention having a triple helical structure may also be described as polypeptides that fold into a triple helix bundle structure.
[0033] The terms "collection" and "library" may be used interchangeably herein. A library may be a collection of polypeptides or polynucleotides. In other words, the library may take the form of a collection or mixture of polypeptides or nucleic acid molecules (polynucleotides), or a plurality of polypeptides or nucleic acid molecules (polynucleotides). A library may be a collection of variants.
[0034] The term "modification" or "amino acid modification" refers to the substitution, deletion, or insertion of an amino acid at a particular position within a polypeptide sequence, where substitution means replacement with another amino acid. Given the known genetic code and recombinant and synthetic DNA techniques, one skilled in the art can readily construct DNA encoding such amino acid variants.
[0035] The term "variant" or "derivative" as used herein includes an amino acid sequence that differs from another amino acid sequence by at least one amino acid substitution, deletion, or insertion. The term "variant" of the present invention may refer to a polypeptide based on SEQ ID NO: 1, for example, with up to 20 amino acid substitutions as compared to SEQ ID NO: 1. Variants of the present invention are characterized by a triple helix motif as defined elsewhere herein. In some embodiments, a variant of a polypeptide of SEQ ID NO: 1 may include a deletion of up to 6 amino acid residues at the N-terminus and / or a deletion of up to 4 amino acid residues at the C-terminus as compared to the amino acid sequence of SEQ ID NO: 1.
[0036] The terms "Fc region" and "Fc domain" may be used interchangeably herein. The Fc region is the tail region of an immunoglobulin, particularly an antibody, that interacts with cell surface receptors, such as those called Fc receptors. Thus, the Fc region or Fc domain refers to the Fc region or Fc domain of an immunoglobulin, particularly an antibody. In various embodiments, the Fc region is derived from a mammalian IgG (antibody), including human IgG, mouse IgG, rat IgG, goat IgG, bovine IgG, guinea pig IgG, and rabbit IgG. The Fc region may be derived from human IgM or human IgA. In various embodiments, the Fc region is derived from a human IgG (antibody), such as human IgG1 (antibody), human IgG2 (antibody), or human IgG4 (antibody), and even more preferably from human IgG1 (antibody). In various embodiments, this Fc region refers to a human IgG1 Fc region having the amino acid sequence of SEQ ID NO:18 or SEQ ID NO:19, or a variant thereof having at least 95%, preferably at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to the amino acid sequence of SEQ ID NO:18 or SEQ ID NO:19.
[0037] As used herein, the term "target" or "target protein" refers to a protein or peptide or fragment thereof, etc., that has an antigen or epitope recognized by a particular binding protein. As described herein, "Fc binding" may be considered to mean interacting with the Fc region of most IgGs with high selectivity and affinity. This binding site is present in a conserved region known as the consensus binding site, which is located in the hinge region between the CH2 and CH3 domains of the Fc region.
[0038] As described herein, a "non-Fc binding polypeptide" refers to a polypeptide that lacks Fc binding, i.e., a polypeptide that lacks detectable interaction with the Fc region of IgG as measured by a suitable method, e.g., SPR analysis, as described below.
[0039] The terms "binding affinity" and "binding activity" may be used interchangeably herein and refer to the ability of a polypeptide of the invention to bind to another protein, peptide, or fragment or domain thereof. Binding affinity is determined by the equilibrium dissociation constant (K D ), which is used to evaluate and rank the strength of bimolecular interactions. Binding affinity and dissociation constants can be measured quantitatively. Methods for determining binding affinity are well known to those skilled in the art and can be selected from, for example, the following methods: surface plasmon resonance (SPR), enzyme-linked immunosorbent assay (ELISA), binding equilibrium exclusion analysis (KinExA assay), biolayer interferometry (BLI), flow cytometry, fluorescence spectroscopy, isothermal titration calorimetry (ITC), analytical ultracentrifugation, radioimmunoassay (RIA or IRMA), and enhanced chemiluminescence (ECL). Typically, the dissociation constant K D is determined at temperatures between the 20's and 30's of °C. Unless otherwise indicated, the K DThe value is determined by SPR at 25°C. A polypeptide having no detectable binding affinity to an immunoglobulin Fc domain as measured by SPR means a polypeptide having no detectable binding affinity to an immunoglobulin Fc domain as measured by SPR at 25°C. The most widely used SPR-based system is BIAcore from BIAcore AB. In various embodiments of the invention, the binding affinity to an immunoglobulin Fc domain may be determined by a BIAcore SPR system. In various embodiments, the concentration of the analyte is 1 μM (see Figures 1 and 2). In various other embodiments, the concentration of the analyte is 10 μM (see Figure 3). Thus, in various embodiments of the invention, it is preferred that the polypeptide of the invention has no detectable binding affinity to an immunoglobulin Fc domain as measured by SPR, in which case the concentration of the analyte in the SPR assay is 1 μM and the binding affinity is determined at 25°C. In various other embodiments of the invention, the polypeptides of the invention have no detectable binding affinity to immunoglobulin Fc domains as measured by SPR, in which case the concentration of the analyte in the SPR assay is preferably 10 μM and the binding affinity is determined at 25° C. The binding affinity to an Ig Fc domain may be measured with reference to a polypeptide having the amino acid sequence of SEQ ID NO: 17 (see, for example, FIG. 1 ), or alternatively with reference to a polypeptide having the amino acid sequence of SEQ ID NO: 16 (see, for example, FIG. 2 or FIG. 3 ). The sequences of SEQ ID NO: 16 and SEQ ID NO: 17 differ at positions 1, 11, 35, and 42 as follows: SEQ ID NO: 16 is 11, 11A, 35R, 42L, and SEQ ID NO: 17 is 1N, 11S, 35K, 42K. Alternatively, the Fc binding affinity may be determined with reference to any Protein A wild type domain or derivative thereof, such as Domain C (SEQ ID NO: 20) or Domain A (SEQ ID NO: 21) or Domain Z (SEQ ID NO: 22). See, for example, FIG. 3 .
[0040] The term "fusion protein" refers to a protein that comprises at least a first protein genetically linked to at least a second protein. Fusion proteins are created by linking two or more genes that originally code for separate proteins. Thus, fusion proteins may comprise multimers of the same or different proteins expressed as a single linear polypeptide.
[0041] As used herein, the term "linker" refers broadly to a molecule that covalently links at least two other molecules.
[0042] The term "amino acid sequence identity" refers to a quantitative comparison of the identity (or difference) of the amino acid sequences of two or more proteins. "Percent (%) amino acid sequence identity" to a reference polypeptide sequence is defined as the percentage of amino acid residues in a sequence that are identical to the amino acid residues in the reference polypeptide sequence after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity. To determine this sequence identity, the sequence of the query protein is aligned to the sequence of the reference protein or polypeptide, e.g., the polypeptide of SEQ ID NO:1. Methods of sequence alignment are well known in the art. For example, the freely available SIM Local similarity program is preferably used to determine the degree of amino acid sequence identity of any polypeptide compared to an amino acid sequence such as SEQ ID NO:1 (Huang and Webb Miller, (1991) Advances in Applied Mathematics 12:337-357). ClustalW can be used for multiple alignment analysis (Thompson et al., (1994) Nucleic Acids Res. 22:4673-4680).
[0043] DETAILED DESCRIPTION OF EMBODIMENTS OF THE PRESENTINVENTION The novel polypeptides of the present invention do not exhibit detectable binding affinity to immunoglobulin Fc domains, for example as measured by SPR. This lack of binding affinity to immunoglobulin Fc domains can be achieved when the polypeptide having a triple helix structure contains an acidic amino acid selected from aspartic acid (D) and glutamic acid (E) in helix 1 at a position corresponding to position 13 of SEQ ID NO: 1, and a basic amino acid selected from any one of arginine (R), lysine (K), and histidine (H) in helix 2 at a position corresponding to position 31 of SEQ ID NO: 1, where helix 1, helix 2, and helix 3 essentially correspond in terms of their positions to positions 7-19, 23-37, and 40-56, respectively, of SEQ ID NO: 1. Table 1 below shows examples of triple helix polypeptides with no detectable immunoglobulin Fc binding.
[0044] TIFF0007591284000001.tif245170
[0045] Table 2 below summarizes the specific amino acids in triple helix polypeptides that do not effect Fc binding. Positions 10, 13, 14, 31, and 35 correspond to positions in SEQ ID NO: 1. D is aspartic acid, R is arginine, and S is serine.
[0046] TIFF0007591284000002.tif73170
[0047] Thus, the present invention provides a non-Fc binding polypeptide comprising an acidic amino acid selected from aspartic acid and glutamic acid at a position corresponding to position 13 of SEQ ID NO:1, and a basic amino acid selected from any one of arginine, lysine, and histidine at a position corresponding to position 31 of SEQ ID NO:1.
[0048] Structural features of specific amino acids at positions 10, 14, and 35 In various embodiments of the present invention, the non-Fc binding polypeptides disclosed herein are further structurally characterized in that they comprise an amino acid residue having a polar side chain at one or more of the positions corresponding in various embodiments to positions 10, 14, and / or 35 of SEQ ID NO:1 in any one of SEQ ID NOs:1-15 and 23-30, preferably an amino acid residue selected from serine (S), threonine (T), glutamine (Q), asparagine (N), and histidine (H). In various embodiments, the polypeptides are further structurally characterized in that they comprise an amino acid residue having a polar side chain at a position corresponding in various embodiments to positions 10, 14, or 35 of SEQ ID NO:1 in any one of SEQ ID NOs:1-15 and 23-30, or positions 10 and 14, or positions 10 and 35, or positions 14 and 35, or positions 10, 14, and 35. Preferably, the non-Fc binding polypeptide disclosed herein is further structurally characterized in that it contains serine at one or more of any one of SEQ ID NOs: 1 to 15 and 23 to 30, and in various embodiments, positions corresponding to positions 10, 14, and 35 of SEQ ID NO: 1. In some embodiments, the non-Fc binding polypeptide disclosed herein is further structurally characterized in that it contains an acidic amino acid at a position corresponding to position 13 of SEQ ID NO: 1, and a basic amino acid at a position corresponding to position 31 of SEQ ID NO: 1, and in various embodiments, serine at all of the positions corresponding to positions 10, 14, and 35 of SEQ ID NO: 1, in any one of SEQ ID NOs: 1 to 15 and 23 to 30, and in various embodiments, positions corresponding to positions 10, 14, and 35 of SEQ ID NO: 1.
[0049] Mutants The present specification also discloses a polypeptide having at least 70% sequence identity to the amino sequence of SEQ ID NO: 1, which is any one of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 23, 24, 25, 26, 27, 28, 29, and 30, in various embodiments, and which comprises an acidic amino acid selected from aspartic acid and glutamic acid at a position corresponding to position 13 of SEQ ID NO: 1, in any one of SEQ ID NO: 1-15 and 23-30, in various embodiments, and a basic amino acid selected from any one of arginine, lysine, and histidine at a position corresponding to position 31 of SEQ ID NO: 1, in any one of SEQ ID NO: 1-15 and 23-30, in various embodiments,
[0050] In various preferred embodiments, any non-Fc binding polypeptide of the invention defined by having at least 70% sequence identity to the amino sequence of any one of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 23, 24, 25, 26, 27, 28, 29, and 30, and in various embodiments, SEQ ID NO: 1, may have at least 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, or 79% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 1-15 and 23-30, and in various embodiments, SEQ ID NO: 1. In other embodiments, the non-Fc binding polypeptide has at least 80% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 1-15 and 23-30, and in various embodiments, SEQ ID NO: 1. In some embodiments, the non-Fc binding polypeptide has at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, or 88% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 1-15 and 23-30, and in various embodiments, SEQ ID NO: 1. In preferred embodiments, the non-Fc binding polypeptide has at least 89% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 1-15 and 23-30, and in various embodiments, SEQ ID NO: 1. In other embodiments, the non-Fc binding polypeptide has at least 90% or 95% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 1-15 and 23-30, and in various embodiments, SEQ ID NO: 1.
[0051] All variants of the non-Fc binding polypeptides of SEQ ID NOs: 1-15 and 23-30 have a triple helical structure as defined anywhere in this specification, have an acidic amino acid at position 13 and a basic amino acid at position 31, and have no detectable binding affinity for an immunoglobulin Fc domain, preferably no detectable binding affinity for an immunoglobulin Fc domain as measured, for example, by surface plasmon resonance.
[0052] Multimers In one embodiment of the present invention, the non-Fc binding protein comprises one, two, three or four copies, preferably one or two copies, of the non-Fc binding protein linked to each other. That is, the non-Fc binding protein can be a monomer, a dimer, a trimer, a tetramer, etc. The multimers of the present invention are artificially produced fusion proteins, typically fusion proteins produced by recombinant DNA techniques well known to those skilled in the art. The non-Fc binding proteins disclosed herein may be prepared by any of a number of conventional and well-known methods, such as simplified organic synthesis or solid-phase supported synthesis, or may be prepared by commercially available automated synthesizers. In some embodiments, the multimers are homomultimers, e.g., the amino acid sequences of the non-Fc binding proteins are identical. In other embodiments, the multimers are heteromultimers, e.g., the amino acid sequences of the non-Fc binding proteins are different.
[0053] Fusion proteins The present specification provides, according to one embodiment, a fusion protein comprising a non-Fc binding polypeptide as disclosed throughout the application. The present specification provides, according to one embodiment, a fusion protein comprising one or more copies, for example two copies, of a non-Fc binding polypeptide as disclosed throughout the application. More specifically, the fusion protein comprises one or more copies of a non-Fc binding polypeptide as disclosed throughout the application and another polypeptide different from the disclosed polypeptide. In various embodiments, the other polypeptide different from the non-Fc binding polypeptide disclosed herein is a target binding protein, preferably an immunoglobulin binding polypeptide or a ubiquitin mutein having binding affinity to a predetermined target. A target binding protein is a polypeptide having the ability to bind to a predetermined target, preferably a protein target. Thus, some embodiments include a fusion protein comprising one or two copies of a non-Fc binding polypeptide and an immunoglobulin binding polypeptide as disclosed herein. Thus, other embodiments include a fusion protein comprising one or two copies of a non-Fc binding polypeptide as disclosed herein and a binding polypeptide having affinity to a predetermined target. Thus, other embodiments include fusion proteins that include one or two copies of a non-Fc binding polypeptide disclosed herein and a ubiquitin-based binding protein (ubiquitin mutein), including a derivative of the human serum protein ubiquitin, such as the well-known Affilin® molecule. Such fusion proteins are also particularly suitable for use in affinity chromatography to purify a given target protein.
[0054] In some embodiments, the fusion protein may comprise, for example, the following combination (from N-terminus to C-terminus): (a) non-Fc binding protein-target binding protein; (b) target binding protein - non-Fc binding protein; (c) non-Fc binding protein-target binding protein-non-Fc binding protein; (d) non-Fc binding protein-non-Fc binding protein-target binding protein; (e) target binding protein-non-Fc binding protein-non-Fc binding protein, and / or (f) target binding protein-non-Fc binding protein-non-Fc binding protein-target binding protein May include:
[0055] In some embodiments, the fusion protein may comprise a non-Fc binding protein selected from the group consisting of SEQ ID NOs: 1-15 and 23-30, or a non-Fc binding protein having at least 90% identity thereto. In some preferred embodiments, the fusion protein may comprise a non-Fc binding protein selected from SEQ ID NO: 1 or SEQ ID NO: 2. In some preferred embodiments, the fusion protein may comprise a non-Fc binding protein selected from SEQ ID NO: 27 or SEQ ID NO: 28, or a non-Fc binding protein having at least 90% identity thereto.
[0056] Such fusion proteins are particularly suitable for use in a Protein A leaching assay to detect Protein A or a Protein A derivative or other immunoglobulin binding proteins during or after affinity chromatography. Protein A or a Protein A derivative or other immunoglobulin binding proteins are quantified by a sandwich immunoassay as described in the Examples. The fusion proteins used in the leaching assay are preferably composed of one or two copies of a non-Fc binding polypeptide as described herein and an Ig binding protein (preferably Protein A or a Protein A derivative or an artificial Ig binding protein). The part of such a fusion protein that contains the non-Fc binding polypeptide does not interfere with the function of the Ig binding protein. An example of improved detectability of a Protein A derivative when fused to at least one copy of a non-Fc binding protein is shown. See FIG. 4.
[0057] Such fusion proteins may be suitable for stabilizing Protein A-based Ig binding proteins, e.g., protein expression is improved when expressed as a fusion protein containing a non-Fc binding polypeptide at the N- or C-terminus.
[0058] Furthermore, fusion proteins comprising at least one copy of a non-Fc binding polypeptide disclosed herein and an Ig binding polypeptide are particularly suitable for use in affinity chromatography due to their beneficial effect on matrix distance.
[0059] The portions of the fusion protein may be directly linked to each other head-to-tail or may be linked by a linker, which is preferably a peptide linker. In various embodiments, a peptide linker may be considered as an amino acid sequence that sterically separates the two portions of the fusion protein. Typically, such linkers are composed of between 1 and 10 amino acids.
[0060] A fusion protein may be characterized as a protein formed by genetically fusing or combining a gene encoding a non-Fc binding polypeptide with a gene encoding a polypeptide other than the polypeptides described herein, and thus may be viewed as the product of two or more genes translated together (with no stop codons between them).
[0061] Library Some embodiments provide a collection of novel polypeptides derived from, based on, or defined by the scaffold sequence of any one of the monomeric non-Fc binding proteins disclosed in SEQ ID NOs: 1-15 and 23-30, and these novel polypeptides form the basis of certain preferred libraries. An advantage of libraries based on such small monomeric scaffold sequences disclosed in the present invention is that proteins identified from such libraries can withstand harsh conditions due to their high structural stability. Furthermore, the non-Fc binding nature of such proteins is advantageous for some applications.
[0062] Some embodiments provide a collection of polypeptides that have no detectable binding affinity to an immunoglobulin Fc domain, characterized in that the collection of polypeptides has a triple helix structure. The polypeptides of the collection that have no detectable binding affinity to an immunoglobulin Fc domain preferably have between 70% and 90%, preferably between 70% and 85%, sequence identity to the amino acid sequences of SEQ ID NOs: 1-15 and 23-30, such as the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 27. Some embodiments provide a library that includes a plurality of variants based on a scaffold such as SEQ ID NO: 1 or SEQ ID NO: 27. These libraries provided herein may include polypeptides of diverse sequences, each of which may contain different amino acid sequences. The sequence differences between members of the library are the source of the diversity present in the library. A randomly modified nucleotide sequence or a randomly modified amino acid sequence is a nucleotide or amino acid sequence in which nucleotide or amino acid substitutions, insertions, or deletions have been made at many positions.
[0063] Such libraries include mutant polypeptides, such as SEQ ID NO:1 or SEQ ID NO:27, that have an acidic amino acid at a position corresponding to position 13 of SEQ ID NO:1 and a basic amino acid at a position corresponding to position 31 of any one of SEQ ID NOs:1-15 and 23-30, in various embodiments, of SEQ ID NO:1, and may be further characterized by specific amino acid residues present at positions corresponding to positions 10, 14, and 35 of any one of SEQ ID NOs:1-15 and 23-30, in various embodiments, of SEQ ID NO:1, as described elsewhere herein. Additionally, in some embodiments, these libraries include mutant non-Fc binding polypeptides, such as any one of SEQ ID NOs:1-15 and 23-30, in various embodiments, of SEQ ID NO:1, that have at least five amino acid substitutions in each of two of the three helices to create a novel interaction site for a preselected non-Fc target, i.e., at least 10 randomized amino acids, such as SEQ ID NO:1 or SEQ ID NO:27. The libraries disclosed herein include mutant polypeptides of SEQ ID NO: 1, in various embodiments, any one of SEQ ID NOs: 1-15 and 23-30, for amino acid randomized positions, preferably within helix 3 and helix 1, or within helix 3 and helix 2, for amino acid randomized positions.
[0064] Accordingly, some embodiments of the invention relate to libraries based on any one of SEQ ID NOs: 1-15 and 23-30, and in various embodiments, non-Fc binding proteins, such as SEQ ID NO: 1, or corresponding triple helix proteins, in which the compounds of the library comprise at least 5 or more mutations at 10-16 randomized positions in two of the following three helices: (a) at least 5 or more mutations at positions selected from position 25, position 26, position 28, position 29, position 30, position 32, position 33, position 35, position 36, and position 37 in helix 2 as shown in SEQ ID NOs: 31 and 32; and (b) at least five or more mutations at positions selected from positions 7, 8, 10, 11, 14, 15, 18, and 20 in helix 1, and five or more mutations at positions selected from positions 42, 43, 46, 47, 49, 50, 53, and 54 in helix 3, as set forth in SEQ ID NO:33 and SEQ ID NO:34. The identification of said positions in helix 1, helix 2, and helix 3 is understood with reference to any one of SEQ ID NOs:1-15 and 23-30, and in various embodiments the corresponding positions in SEQ ID NO:1. In some embodiments the substitution may be with any amino acid except C, G, N, or P. This is because cysteine is a reactive amino acid and can form disulfide bonds with other cysteine-containing polypeptides, glycine and proline are known to destabilize helical structures, and finally asparagine is particularly sensitive to corrosive treatments that cause degradation.
[0065] In some embodiments, the non-Fc binding polypeptide having a triple helical structure comprises or consists of the amino acid sequence of any one of SEQ ID NOs: 31, 32, 33, or 34.
[0066] Library construction method The present invention provides methods for making such libraries, as well as the libraries described elsewhere herein. A state-of-the-art library synthesis method, the preferred Triplet Technology (Morphosys Slonomics), allows for the synthesis of random libraries with a distribution of, for example, the 20 natural amino acids or selected amino acids. Assuming a random distribution of these 20 natural amino acids at positions 7 to 16, for example, the polypeptide of SEQ ID NO: 1 or the polypeptides of SEQ ID NOs: 2 to 15 and 23 to 30, the number of amino acids is 20 to the power of 7 (20 7 ) to the power of 16(20 16 A pool of unique mutants is generated. The genes / proteins of this pool constitute a library of these mutants of the non-Fc binding protein of SEQ ID NO: 1 or the non-Fc binding proteins of SEQ ID NOs: 2-15 and 23-30.
[0067] Library Display The library is displayed on the surface of ribosomes, bacteriophages, viruses, bacteria, or yeast cells, preferably on ribosomes and bacteriophages, as conjugates to RNA, and multiple rounds of panning are repeated for each target. It is preferred to carry out the contacting according to the present invention by a suitable display and selection method, such as phage display, ribosome display, mRNA display or cell surface display, yeast surface display or bacterial surface display, preferably phage display or ribosome display. These methods mentioned herein are known to those skilled in the art.
[0068] In the phage display method described herein, recombinant variants of SEQ ID NO:1 or the corresponding non-Fc binding scaffold amino acid sequence are displayed on filamentous phages, and the coding DNA of the displayed variants is simultaneously packaged in a single-stranded state within the phage envelope. Thus, within the framework of affinity enrichment, variants with certain properties can be selected from the library, and their genetic information can be amplified by infecting appropriate bacteria or by subjecting them to another enrichment cycle, respectively. The display of variants of SEQ ID NO:1 or the corresponding non-Fc binding scaffold amino acid sequence on the phage surface is achieved by genetic fusion of a signal sequence to a capsid protein or a surface protein of the phage. Furthermore, the encoded protein can contain other functional sequences, such as affinity tags or antibody epitopes for detection and / or purification by affinity chromatography, or protease recognition sequences for specific cleavage of the protein during this affinity enrichment process.
[0069] Library selection method In another aspect, the present invention provides a method for selecting one or more of scaffold variants of SEQ ID NO:1 or a corresponding non-Fc binding scaffold amino acid sequence having a particular binding affinity for a target protein or target peptide from a library comprising said scaffold variants, comprising the steps of: (a) providing a library comprising scaffold variants of SEQ ID NO:1 or a corresponding non-Fc binding scaffold amino acid sequence; (b) contacting said library with said target protein or target peptide under conditions allowing interaction of one or more variant polypeptides of SEQ ID NO:1 or the corresponding non-Fc binding scaffold amino acid sequence with said target protein or target peptide for a time sufficient for said interaction; and (c) selecting from 10 or more scaffold variants of SEQ ID NO:1 or a corresponding non-Fc binding scaffold amino acid sequence. -5 ~10 -12 A specific binding affinity (K D (i) selecting (identifying) from said library one or more variant polypeptides of SEQ ID NO:1 or a corresponding non-Fc binding scaffold amino acid sequence having the sequence:
[0070] Mutant selection method Suitable for the screening method to isolate variants of SEQ ID NO:1 or the corresponding non-Fc binding scaffold amino acid sequence are bacterial vectors called phagemids into which the described gene cassettes of the fusion proteins are inserted. Among other things, the phagemids contain the intergenic region or part thereof of a filamentous phage (e.g. M13 or f1) which allows the covalently closed circular phagemid DNA to be packaged into a phage capsid upon superinfection of a bacterial cell carrying the phagemid with a helper phage.
[0071] The resulting phage particles can be selected by methods known to those skilled in the art for the binding of variants of SEQ ID NO:1 or the corresponding non-Fc binding scaffold amino acid sequence disclosed herein displayed on them to any target. For this purpose, these displayed variants of SEQ ID NO:1 or the corresponding non-Fc binding scaffold amino acid sequence can be temporarily immobilized on a target material and the variants that do not bind can be specifically eluted after isolating them. These phage particles thus obtained can be re-amplified and enriched by successive cycles of selection and amplification of variants of SEQ ID NO:1 or the corresponding non-Fc binding scaffold amino acid sequence with binding properties to a selected target.
[0072] Variants of SEQ ID NO:1 or corresponding non-Fc binding scaffold amino acid sequences from the enriched phage pool are cloned into expression vectors for individual protein expression. Preferably, expression of variants of SEQ ID NO:1 or corresponding non-Fc binding scaffold amino acid sequences disclosed herein allows screening for specific binding proteins by established techniques such as ELISA on an automated high-throughput screening platform. Identified clones with the desired binding properties can then be sequenced to reveal the amino acid sequence. The identified proteins may be subjected to additional maturation steps, for example by generating additional libraries based on altering the identified sequence and repeating the phage display, ribosome display, panning, and screening steps as described herein. These expressed proteins are contacted with a target protein, allowing these partners to bind to each other. This process allows the identification of proteins with binding activity for this given target protein.
[0073] The present invention enables one skilled in the art to enrich for a curated collection of variants of SEQ ID NO:1 or a corresponding non-Fc binding scaffold amino acid sequence that are functional except for having no detectable binding affinity for an immunoglobulin Fc domain as measured by a suitable method, such as SPR, and that are capable of binding to a given target.
[0074] Methods for Producing Polypeptides The present invention further relates to a method for producing a novel non-Fc binding polypeptide as disclosed herein having a binding affinity to a predefined target protein, comprising the steps of: (i) providing a collection of polypeptides as disclosed herein; (ii) contacting the collection of polypeptides of (i) with a target protein; (iii) identifying a complex comprising a non-Fc binding polypeptide as disclosed herein bound to said target protein; and (iv) obtaining a non-Fc binding polypeptide as disclosed herein capable of binding to said target protein. Non-specific binding polypeptides can be removed by several washing steps. Proteins having a specific binding affinity to said target protein remain attached to said target protein. After elution from the target protein, the polypeptides can be amplified and subjected to one or more contacting steps with said target protein. The present disclosure encompasses such non-Fc binding polypeptides having a binding affinity to a target molecule obtained or obtainable or produced or prepared by the aforementioned method.
[0075] The method for generating a novel non-Fc binding polypeptide with binding affinity for a target molecule may comprise the additional step after step (iii) and before step (iv) of determining the binding affinity of the polypeptide for the target protein. This binding affinity may be determined as described elsewhere herein.
[0076] Some embodiments relate to a method for producing a polypeptide of any one of SEQ ID NOs: 1-15 and 23-30, and in various embodiments a mutant protein derived from the polypeptide of SEQ ID NO: 1, comprising the steps of: (i) performing mutagenesis on a triplet of a nucleic acid molecule encoding the amino acid sequence of a polypeptide of any one of SEQ ID NOs: 1-15 and 23-30, wherein the triplet is modified in at least five selected positions in each of helix 3 and helix 2, or at least five selected positions in each of helix 3 and helix 1; (ii) obtaining one or more mutant nucleic acid molecules; (iii) expressing the one or more mutant nucleic acid molecules obtained in (ii) in a suitable expression system; and (iv) enriching the one or more mutant proteins by selection and / or isolation.
[0077] In said mutations, any structural technical features according to the aspects and embodiments described anywhere herein may be taken into account.
[0078] Use of the Novel Polypeptides in Technical Applications The present specification also provides for the use of any of the novel polypeptides of the present invention, including the novel polypeptides having binding affinity for a target protein obtained by the methods described herein, in technical applications, preferably in affinity chromatography.
[0079] As described herein, affinity chromatography (also called affinity purification) utilizes specific binding interactions between molecules. For example, a fusion protein comprising any one of the non-Fc binding proteins of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 23, 24, 25, 26, 27, 28, 29, and 30, and proteins at least 90% identical thereto, can be used in a leaching assay as described herein. Additionally, any one of the non-Fc binding proteins of SEQ ID NOs: 1-15 and 23-30, and proteins at least 90% identical thereto, can be immobilized on a solid support as a spacer for a binding protein as described herein. Methods of protein immobilization and affinity chromatography are well known in the art of protein engineering and protein purification, and those skilled in the art can easily carry out these methods using standard techniques and equipment.
[0080] In various embodiments, the affinity purification method may further comprise one or more washing steps carried out under conditions sufficient to remove from the affinity separation matrix some or all of the molecules that are non-specifically bound to the affinity separation matrix. Affinity separation matrices suitable for the uses and methods of the present disclosure are those according to the aspects and embodiments described herein and known to those of skill in the art.
[0081] Binding to solid support In various aspects and / or embodiments of the invention, the novel polypeptides disclosed herein, including novel polypeptides made or obtained by any of the methods described herein, are attached to a solid support. In some embodiments of the invention, the polypeptides comprise attachment sites for site-specific covalent attachment of the polypeptide to a solid support. Specific attachment sites include, but are not limited to, natural amino acids, such as cysteine or lysine, that allow for a specific chemical reaction with a reactive group of the solid phase or with a linker present between the solid phase and the protein.
[0082] In some embodiments, the non-Fc binding proteins may include additional amino acid residues at the N-terminus and / or C-terminus, such as additional sequences at the N-terminus and / or C-terminus, with or without a tag.
[0083] Affinity Separation Matrix In another embodiment, an affinity separation matrix is provided that comprises a non-Fc binding polypeptide, including a polypeptide identified by any of the methods described herein, In various embodiments, the affinity separation matrix can be an affinity purification matrix.
[0084] In a preferred embodiment, the affinity separation matrix is a solid support. The affinity separation matrix comprises at least one non-Fc binding polypeptide provided by the present invention. Thus, any of the novel non-Fc binding proteins that are polypeptides disclosed herein are encompassed for use in protein separation and / or purification by affinity (separation / purification) matrices.
[0085] Solid support matrices for affinity chromatography are known in the art and include, but are not limited to, agarose and stabilized agarose derivatives, cellulose or cellulose derivatives, porous glass, monoliths, silica, zirconium oxide, titanium oxide, or synthetic polymeric compounds, and hydrogels of various compositions.
[0086] The format of the solid support matrix can be any suitable type of well-known format, such solid support matrices for binding the novel proteins or polypeptides of the invention can include, for example, but are not limited to, one of the following: columns, capillaries, particles, membranes, filters, monoliths, fibers, pads, gels, slides, plates, cassettes, or any other formats commonly used in chromatography and known to those of skill in the art.
[0087] In one embodiment, the matrix is composed of substantially spherical particles, also known as beads, such as sepharose beads or agarose beads. Particulate matrices can be used as packed beds or in suspension, including swollen beds. In other embodiments of the invention, the solid support matrix is a membrane, such as a hydrogel membrane. In some embodiments, the affinity purification may require a membrane as the matrix to which the protein of the invention is covalently attached. The solid support may be in the form of a membrane in a cartridge.
[0088] In some embodiments, the affinity purification requires a chromatography column containing a solid support matrix to which the novel protein of the invention is covalently attached. The novel protein or polypeptide of the invention can be attached to a suitable solid support matrix by conventional coupling techniques. Methods for immobilizing protein ligands on solid supports are well known in the art of protein engineering and protein purification, and those skilled in the art can easily carry out these methods using standard techniques and equipment.
[0089] composition Further provided herein are compositions comprising non-Fc binding polypeptides as disclosed throughout this application, including novel non-Fc binding polypeptides having binding affinity for a target protein obtained by the corresponding methods described herein. In various embodiments, such compositions comprise a diagnostically or therapeutically effective dose or amount of the novel non-Fc binding polypeptide. The amount of protein administered may depend, inter alia, on the organism being treated, the type of disease, the age and weight of the patient, and other factors.
[0090] In various embodiments, the composition is a diagnostic composition comprising a non-Fc binding polypeptide and a diagnostically acceptable carrier. In various other embodiments, the composition is a pharmaceutical composition comprising a non-Fc binding polypeptide and a pharma- ceutically acceptable carrier. These compositions optionally contain other auxiliary agents and excipients known to those of skill in the art, including, but not limited to, stabilizers, surfactants, salts, buffers, colorants, and the like.
[0091] Compositions comprising at least one non-Fc binding polypeptide can be prepared by methods known in the art, for example, the type of pharmaceutical formulation may depend on the particular disease being treated, the route of administration, the severity of the disease, the patient being treated, and other factors known to those skilled in the medical arts.
[0092] The present specification further provides the use of any novel non-Fc binding polypeptide, including novel polypeptides having binding affinity for a target protein obtained by the corresponding methods described herein, or the use of the compositions described herein as compositions, pharmaceuticals, diagnostics, and / or prognostic agents.
[0093] Method for reducing the binding affinity of a polypeptide having a triple helical structure to an immunoglobulin Fc domain - Patents.com The present invention also provides a method for reducing or attenuating the binding affinity of a polypeptide having a triple helical structure to an immunoglobulin Fc domain, the method comprising: (a) selecting at least two amino acid positions in helix 1 and helix 2 for mutagenesis, for helix 1 and helix 2 corresponding in terms of position to positions 7 to 19 and positions 23 to 37 of SEQ ID NO: 1, respectively, wherein positions corresponding to positions 13 and position 31 in the amino acid sequence of SEQ ID NO: 1 are selected as the at least two amino acid positions for mutagenesis; and (b) performing mutagenesis on the at least two amino acid positions selected for mutagenesis, the mutagenesis comprising substituting the amino acid at the position corresponding to position 13 of SEQ ID NO: 1 with an acidic amino acid selected from aspartic acid and glutamic acid, and substituting the amino acid at the position corresponding to position 31 of SEQ ID NO: 1 with a basic amino acid selected from any one of arginine, lysine, and histidine. Preferably, the mutation comprises a substitution of the amino acid at the position corresponding to position 13 of SEQ ID NO:1 with aspartic acid, and a substitution of the amino acid at the position corresponding to position 31 of SEQ ID NO:1 with arginine.
[0094] In still other preferred embodiments of the methods described herein, the mutation may further comprise substituting one or more of the amino acids at positions corresponding to positions 10, 14, and 35 in the amino acid sequence of any one of SEQ ID NOs: 1-15 and 23-30, in various embodiments, to any amino acid residue, preferably an amino acid residue having a polar side chain, more preferably an amino acid residue selected from serine, threonine, glutamine, asparagine, and histidine, even more preferably serine. The present invention encompasses polypeptides having a triple helical structure prepared according to the methods described herein that reduce or attenuate the binding affinity of the polypeptide having a triple helical structure to an immunoglobulin Fc domain.
[0095] The mutation may involve substituting an amino acid at positions corresponding to positions 10 and 14, or positions 10 and 35, or positions 14 and 35, or positions 10, 14, and 35 in the amino acid sequence of SEQ ID NO: 1 of any one of SEQ ID NOs: 1-15 and 23-30, in various embodiments, with an amino acid residue, preferably an amino acid residue having a polar side chain.
[0096] The mutation preferably includes a substitution of one or more of the amino acids at positions corresponding to positions 10, 14, and 35 in the amino acid sequence of SEQ ID NO: 1 in any one of SEQ ID NOs: 1 to 15 and 23 to 30 in various embodiments, with serine, and more preferably includes a substitution of two of the amino acids at positions corresponding to positions 10, 14, and 35 in the amino acid sequence of SEQ ID NO: 1 in any one of SEQ ID NOs: 1 to 15 and 23 to 30 in various embodiments, with serine, and those two amino acid positions include positions corresponding to positions 10 and 14, positions 10 and 35, and positions 14 and 35, respectively, in any one of SEQ ID NOs: 1 to 15 and 23 to 30 in various embodiments, in SEQ ID NO: 1. In a particularly preferred embodiment, the mutation includes a substitution of all of the amino acids at positions corresponding to positions 10, 14, and 35 in the amino acid sequence of SEQ ID NO: 1 in any one of SEQ ID NOs: 1 to 15 and 23 to 30 in various embodiments, with serine.
[0097] In another preferred embodiment, the mutation comprises substituting one or more of the amino acids at positions corresponding to positions 10, 14, and 35 in the amino acid sequence of SEQ ID NO: 1 in any one of SEQ ID NOs: 1 to 15 and 23 to 30 in various embodiments, with threonine, and more preferably comprises substituting an amino acid at two of the positions corresponding to positions 10, 14, and 35 in SEQ ID NO: 1 in any one of SEQ ID NOs: 1 to 15 and 23 to 30 in various embodiments, with threonine, and those two amino acid positions include positions corresponding to positions 10 and 14, positions 10 and 35, and positions 14 and 35, respectively, of SEQ ID NO: 1 in any one of SEQ ID NOs: 1 to 15 and 23 to 30 in various embodiments.
[0098] In a particularly preferred embodiment, the mutation comprises substituting all of the amino acids at positions corresponding to positions 10, 14, and 35 in the amino acid sequence of any one of SEQ ID NOs: 1-15 and 23-30, and in various embodiments SEQ ID NO: 1, with threonine. As described herein, serine residues are preferred over threonine residues at any one of positions corresponding to positions 10, 14, and 35 in SEQ ID NO: 1, and in various embodiments SEQ ID NO: 1.
[0099] In various embodiments of the methods described herein, the mutation may comprise substituting an amino acid at a position corresponding to position 13 of any one of SEQ ID NOs: 1-15 and 23-30, in various embodiments, of SEQ ID NO: 1, with aspartic acid, and in a position corresponding to position 31 of any one of SEQ ID NOs: 1-15 and 23-30, in various embodiments, of SEQ ID NO: 1, with a basic amino acid selected from any one of arginine, lysine, and histidine. The mutation may comprise substituting an amino acid at a position corresponding to position 13 of SEQ ID NO: 1, with glutamic acid, and in a position corresponding to position 31 of any one of SEQ ID NOs: 1-15 and 23-30, in various embodiments, of SEQ ID NO: 1, with a basic amino acid selected from any one of arginine, lysine, and histidine.
[0100] In other preferred embodiments of the methods described herein, the mutation may comprise a substitution of the amino acid at a position corresponding to position 13 of any one of SEQ ID NOs: 1-15 and 23-30, in various embodiments, to aspartic acid or glutamic acid, and a substitution of the amino acid at a position corresponding to position 31 of any one of SEQ ID NOs: 1-15 and 23-30, in various embodiments, to arginine. In other preferred embodiments of the methods described herein, the mutation may comprise a substitution of the amino acid at a position corresponding to position 13 of any one of SEQ ID NOs: 1-15 and 23-30, in various embodiments, to aspartic acid or glutamic acid, and a substitution of the amino acid at a position corresponding to position 31 of any one of SEQ ID NOs: 1-15 and 23-30, in various embodiments, to lysine. In other preferred embodiments of the methods described herein, the mutation may include substituting the amino acid at a position in any one of SEQ ID NOs: 1-15 and 23-30, and in various embodiments corresponding to position 13 of SEQ ID NO: 1, with aspartic acid or glutamic acid, and substituting the amino acid at a position in any one of SEQ ID NOs: 1-15 and 23-30, and in various embodiments corresponding to position 31 of SEQ ID NO: 1, with histidine.
[0101] In further preferred embodiments of the methods described herein, the mutation may comprise substituting an amino acid at a position corresponding to position 13 of any one of SEQ ID NOs: 1-15 and 23-30, in various embodiments, of SEQ ID NO: 1, with aspartic acid, and a substitution of an amino acid at a position corresponding to position 31 of any one of SEQ ID NOs: 1-15 and 23-30, in various embodiments, of SEQ ID NO: 1, with lysine. In other preferred embodiments of the methods described herein, the mutation may comprise substituting an amino acid at a position corresponding to position 13 of any one of SEQ ID NOs: 1-15 and 23-30, in various embodiments, of SEQ ID NO: 1, with aspartic acid, and a substitution of an amino acid at a position corresponding to position 31 of any one of SEQ ID NOs: 1-15 and 23-30, in various embodiments, of SEQ ID NO: 1, with histidine. In other preferred embodiments of the methods described herein, the mutation may comprise a substitution of the amino acid at a position corresponding to position 13 of any one of SEQ ID NOs: 1-15 and 23-30, in various embodiments, to glutamic acid, and a substitution of the amino acid at a position corresponding to position 31 of any one of SEQ ID NOs: 1-15 and 23-30, in various embodiments, to arginine. In other preferred embodiments of the methods described herein, the mutation may comprise a substitution of the amino acid at a position corresponding to position 13 of any one of SEQ ID NOs: 1-15 and 23-30, in various embodiments, to glutamic acid, and a substitution of the amino acid at a position corresponding to position 31 of any one of SEQ ID NOs: 1-15 and 23-30, in various embodiments, to lysine. In other preferred embodiments of the methods described herein, the mutation may include substituting the amino acid at a position in any one of SEQ ID NOs: 1-15 and 23-30, and in various embodiments corresponding to position 13 of SEQ ID NO: 1, with glutamic acid, and substituting the amino acid at a position in any one of SEQ ID NOs: 1-15 and 23-30, and in various embodiments corresponding to position 31 of SEQ ID NO: 1, with histidine.
[0102] The methods described herein for reducing or attenuating the binding affinity of a polypeptide having a triple helical structure to an immunoglobulin Fc domain include reducing or attenuating the binding affinity of a polypeptide having a triple helical structure, as described elsewhere herein, further characterized in various embodiments as having at least 70% sequence identity to the amino sequence of any one of SEQ ID NOs: 1-15 and 23-30, SEQ ID NO: 1. This includes any variant non-Fc binding polypeptide of SEQ ID NOs: 1-15 and 23-30 disclosed herein, and in particular those variant polypeptides having more specific characteristics in terms of percent sequence identity to the amino sequence of any one of SEQ ID NOs: 1-15 and 23-30, SEQ ID NO: 1. Thus, the present invention encompasses a method for reducing or attenuating the binding affinity of a polypeptide having a triple helical structure to an immunoglobulin Fc domain, comprising: (a) selecting positions 13 and 31 in the amino acid sequence of any one of SEQ ID NOs: 1-15 and 23-30, and in various embodiments SEQ ID NO: 1; and (b) performing mutagenesis at the at least two amino acid positions selected for mutagenesis, the mutagenesis comprising substituting an amino acid at a position corresponding to position 13 of any one of SEQ ID NOs: 1-15 and 23-30, and in various embodiments SEQ ID NO: 1, with an acidic amino acid selected from aspartic acid (D) and glutamic acid (E), and substituting an amino acid at a position corresponding to position 31 of any one of SEQ ID NOs: 1-15 and 23-30, and in various embodiments SEQ ID NO: 1, with a basic amino acid selected from any one of arginine (R), lysine (K), and histidine (H).
[0103] In various embodiments, the polypeptide having a triple helical structure created or prepared or obtained or obtainable by the methods disclosed herein for reducing the binding affinity of a polypeptide having a triple helical structure to an immunoglobulin Fc domain does not have a detectable binding affinity to an immunoglobulin Fc domain as measured by a suitable method, such as surface plasmon resonance.
[0104] Preferred embodiments include mutant polypeptides of any one of SEQ ID NOs: 1-15 and 23-30, and in various embodiments SEQ ID NO: 1. Some embodiments include non-Fc binding polypeptides having a triple helix structure and having at least 70% sequence identity to the amino sequence of any one of SEQ ID NOs: 1-15 and 23-30, and in various embodiments SEQ ID NO: 1, where the polypeptide (a) comprises an acidic amino acid residue, preferably an aspartic acid (D) residue, at a position corresponding to position 13 of any one of SEQ ID NOs: 1-15 and 23-30, and in various embodiments SEQ ID NO: 1, and (b) comprises a basic amino acid residue, preferably an arginine (R) residue, at a position corresponding to position 31 of any one of SEQ ID NOs: 1-15 and 23-30, and in various embodiments SEQ ID NO: 1. Such polypeptides preferably contain at least any of 5, 6, 7, or 8 amino acid substitutions in helix 3, where helix 3 contains amino acid residues selected from any one of SEQ ID NOS: 1-15 and 23-30, and in various embodiments, corresponding to positions 40-56 of SEQ ID NO: 1, preferably positions 42, 43, 44, 46, 47, 49, 50, 51, 53, and 54 of SEQ ID NO: 1. Furthermore, such proteins contain at least any of 6, 7, or 8 amino acid substitutions at a position including an amino acid residue in helix 1 and a position including the first residue immediately adjacent to helix 1, where helix 1 contains amino acid residues selected from any one of SEQ ID NOS: 1-15 and 23-30, and in various embodiments, corresponding to positions 7-19 of SEQ ID NO: 1, preferably positions 7, 8, 10, 11, 14, 15, 18, and 20.In some embodiments, such proteins comprise at least 5, 6, 7, or 8 amino acid substitutions in helix 3, where helix 3 comprises an amino acid residue selected from among any one of SEQ ID NOS: 1-15 and 23-30, in various embodiments corresponding to positions 40-56 of SEQ ID NO:1, preferably positions 42, 43, 44, 46, 47, 49, 50, 51, 53, and 54 of SEQ ID NO:1, and at least 5, 6, 7, or 8 amino acid substitutions at positions including amino acid residues in helix 2, where helix 2 comprises an amino acid residue selected from among any one of SEQ ID NOS: 1-15 and 23-30, in various embodiments corresponding to positions 23-37 of SEQ ID NO:1, preferably positions 24, 25, 26, 27, 28, 29, 30, 32, 33, 35, 36, and 37.
[0105] Polynucleotides, Vectors, and Host Cells An embodiment is provided that includes an isolated polynucleotide or nucleic acid molecule that encodes a polypeptide disclosed herein. Other embodiments also include a polypeptide encoded by said polynucleotide disclosed herein. Vectors, particularly expression vectors, that include said isolated polynucleotide or nucleic acid molecule of the present invention are further provided, as are host cells that include said isolated polynucleotide or said expression vector. For example, one or more polynucleotides that encode a polypeptide disclosed herein may be expressed in a suitable host, and the protein so produced can be isolated. A vector refers to any molecule or entity (e.g., nucleic acid, plasmid, bacteriophage, or virus) that can be used to transfer protein coding information into a host cell. Suitable vectors that can be applied to the present invention are known in the art.
[0106] Further provided is an isolated cell comprising the polynucleotide or nucleic acid or vector. Suitable host cells include prokaryotic or eukaryotic cells, such as a host cell carrying a vector or a non-human host (cell). A host cell is a cell that has been transformed with a nucleic acid sequence or can be transformed with a nucleic acid sequence, thereby expressing a gene of interest. Suitable bacterial expression host cells or bacterial expression systems are known in the art. Various mammalian or insect cell culture systems known in the art can also be used to express recombinant proteins.
[0107] Method for Producing the Protein of the Present Invention In another embodiment there is provided a method for producing a non-Fc binding polypeptide as described, said method comprising the steps of (a) culturing a (suitable) host cell under conditions suitable for expression of said non-Fc binding polypeptide to obtain said non-Fc binding polypeptide, and (b) optionally isolating said non-Fc binding polypeptide. Suitable conditions for the culture of prokaryotic or eukaryotic hosts are well known to those skilled in the art.
[0108] The non-Fc binding polypeptides may be prepared by any conventional and well-known method, such as simplified organic synthesis or solid-supported synthesis, or may be prepared by commercially available automated synthesizers. These polypeptides may also be prepared by conventional recombinant techniques alone or in combination with conventional synthetic techniques.
[0109] In one embodiment, there is provided a method for preparing a non-Fc binding polypeptide as detailed herein, comprising the steps of: (a) providing a nucleic acid molecule encoding a non-Fc binding polypeptide; (b) introducing said nucleic acid molecule into an expression vector; (c) introducing said expression vector into a host cell; (d) culturing said host cell in a medium; and (e) producing a non-Fc binding polypeptide by exposing said host cell to culture conditions suitable for expression of said non-Fc binding polypeptide, optionally comprising (f) isolating the protein or polypeptide produced in step (e); and optionally comprising (g) binding said protein or polypeptide to a solid matrix as described herein. In various embodiments of the invention, production of said non-Fc binding polypeptide is performed by cell-free in vitro transcription and translation.
[0110] The entire disclosure of the priority application, European Patent Application No. EP18205679.6, is incorporated herein by reference, which means that the entire disclosure content of European Patent Application No. EP18205679.6 is considered to form part of the disclosure content of the present application. EXAMPLES
[0111] The following examples are provided to further illustrate the present invention. However, the present invention is not limited to these examples, and the following examples merely demonstrate the feasibility of the present invention based on the above description. Reference is also made to the references cited in this application for a complete disclosure of the present invention, and the references are fully incorporated into this application by reference.
[0112] Example 1. Protein expression and purification All constructs were expressed in E. coli strain BL21(DE3) using a low copy number plasmid system under the control of the T7 promoter. Proteins were produced in soluble form in the cytoplasm after induction with lactose in the medium (autoinduction medium). The expression plasmids were transformed into BL21(DE3) competent cells, which were spread on selective agar plates (kanamycin) and grown overnight at 37°C. A single colony was inoculated into 3 ml of 2xYT medium supplemented with kanamycin at 50 μg / ml as a preculture, which was grown in a culture tube at 37°C and 200 rpm in a conventional rotary shaker for 6 hours. The main culture was inoculated with 3 ml of preculture into 300 ml of ZYM-5052 (0.5% glycerol, 0.2% lactose, 0.05% glucose, 0.5% yeast extract, 1.0% casamino acids, 25 mM Na2HPO4, 25 mM KH2PO4, 5 mM Na2SO4, 2 mM MgSO4, and trace elements; see Studier, 2005) supplemented with kanamycin to 50 μg / ml in a 1 L Erlenmeyer flask. The culture was transferred to a rotary incubator and grown at 30°C and 200 rpm. Expression of the recombinant protein was induced by allowing lactose to enter the cells after glucose was metabolized. The cells were grown overnight for approximately 17 hours to a final OD600 of approximately 2-4. OD600 was measured before harvesting and a sample adjusted to OD600 of 0.6 was removed, pelleted, and frozen at -20°C. To collect the biomass, cells were centrifuged at 12000 x g for 15 min at 22°C. The weight of the pellet (wet weight) was measured. Cells were stored at -20°C before processing.
[0113] Proteins with affinity tags were purified by affinity chromatography and size exclusion. After affinity chromatography purification, size exclusion chromatography (SE HPLC or SEC) was performed using an Akta system and a Superdex™ 200 HiLoad 16 / 600 column (GE Healthcare). The SEC column had a volume of 120 ml and was equilibrated with 2 column volumes (CV). Samples were loaded at a flow rate of 1 ml / min. Fraction collection began when the signal intensity reached 10 mAU. Positive fractions were pooled after SDS-PAGE analysis and their protein concentrations were measured. Other analyses included SDS-PAGE, SE-HPLC, and RP-HPLC. Protein concentrations were determined by absorbance measurements at 280 nm using the molar extinction coefficient. Reverse phase chromatography (RP-HPLC) was performed using a Dionex HPLC system and a PLRP-S (5 μm, 300A) column (Agilent).
[0114] Example 2. Analysis of proteins by surface plasmon resonance (SPR) 500-1500 RU of IgG1-Fc domain (off-ligand) was immobilized on a CM-5 sensor chip (GE Healthcare) and the chip was equilibrated using SPR running buffer. The exposed carboxyl groups on the surface were activated by passing a mixture of EDC and NHS to obtain reactive ester groups. Upon ligand binding, protein analytes accumulated on the surface and the refractive index increased. The change in refractive index was measured in real time and plotted as response units or resonance units against time. The analytes were serially diluted and loaded onto the chip at a flow rate of 30 μl / min. Binding was performed for 120 s and dissociation was performed for 360 s. After each experiment, the chip surface was regenerated using 30 μl of regeneration buffer (10 mM HCL) and equilibrated using running buffer. Binding studies were performed by using a BIAcore 3000 (GE Healthcare) and data evaluation was performed using the Langmuir 1:1 model (Rl=0) with the BIAevaluation 3.0 software provided by the manufacturer. The estimated dissociation constant (K D ) were normalized to off-targets and displayed. Figure 1 shows the binding affinity of the polypeptide of SEQ ID NO: 17 and the polypeptide of SEQ ID NO: 9 to IgG1-Fc. Shown is the change in refractive index measured in real time and plotted as response units or resonance units [RU] against time [sec].
[0115] Binding affinities to the IgG-Fc domain were measured with reference to SEQ ID NO: 17 (see FIG. 1) or SEQ ID NO: 16 (see FIG. 2 and FIG. 3) or the wild-type protein domain (see FIG. 3) or domain Z (see FIG. 3). A K of 3 nM for c27 was obtained after fitting the data to a Langmuir 1:1 model. D The value was calculated and for SEQ ID NO: 9, K D For example, SEQ ID NO:16 has a K of 1.15 nM for binding to IgG1. D Domain C (SEQ ID NO:20) has a K D It has.
[0116] Example 3. Extravasation assay using fusion proteins containing non-Fc binding proteins of the present invention In affinity chromatography, it is important to ensure low levels of leached Protein A derivatives or immunoglobulin binding proteins in order to obtain reliable results. A Protein A ELISA kit for the detection of native and recombinant Protein A (Repligen, Cat. No. 9000-1) was used for the leaching assay according to the manufacturer's instructions. The fusion proteins tested were SEQ ID NO:1 fused N-terminally to proteins BP1 or BP3 with binding affinity to a target, SEQ ID NO:1 fused C-terminally to proteins BP1 or BP3 with binding affinity to a target, and SEQ ID NO:1 fused N- and C-terminally to proteins BP2 with binding affinity to a target. BP1, BP2, and BP3 are proteins consisting of 58 amino acids containing a triple helix structure with specific affinity to a target. For example, BP3 has 75.8% identity to SEQ ID NO:1, and BP3 is a non-Fc binding protein containing modifications in helix 2 and helix 3 compared to SEQ ID NO:1. Figure 4 shows the improved recovery of fusion proteins of SEQ ID NO:1 with derivatives with specific target binding properties.
[0117] Example 4. Library construction, library duplication, and mutant selection Library Building and Library Cloning Scaffold SEQ ID NO:1 (PAdelFc): IAAKFD EAQSAADSEILHL PNL TEEQRNAFRQSLSDD P.S. VSLEVLGEAQKLNDSQA Penalty kick Amino acid residues 7-19 (helix 1), amino acid residues 23-37 (helix 2), and amino acid residues 40-56 (helix 3) are underlined.
[0118] Libraries containing randomized amino acid positions were either synthesized by Triplet Technology (ThermoFisher Scientific, GeneArt, Germany) to average the amino acid distribution at the randomized positions while excluding cysteine and other amino acid residues, or were synthesized in-house by randomized oligonucleotides made with synthetic trinucleotide phosphoramidites (ELLA deisBiotech). PAdelFc (SEQ ID NO: 1) was randomized at least 5 amino acid positions in helix 3 and helix 2, or in helix 3 and helix 1. The following libraries were generated based on SEQ ID NO: 1: Library PA02 (SEQ ID NO: 31): positions (25, 26, 28, 29, 30, 32, 33, 35, 36) in helix 2 and positions (42, 43, 44, 46, 47, 50, 54) in helix 3 are randomized. Library PA12 (SEQ ID NO: 32): positions (25, 29, 30, 32, 33, 36, 37) in helix 2 and positions (43, 46, 47, 50, 51) in helix 3 are randomized. Library PA03 (SEQ ID NO: 33): positions (7, 8, 10, 11, 14, 15, 18, 20) in helix 1 and positions (42, 43, 46, 47, 49, 50, 53, 54) in helix 3 are randomized. Library PA13 (SEQ ID NO: 34): positions (7, 8, 11, 14, 15, 18) in helix 1 and positions (42, 46, 49, 50, 53) in helix 3 are randomized.
[0119] cDNA libraries corresponding to PA02 and PA03 were provided by ThermoFisher Scientific as GeneArt string DNA fragments. The coding regions, including helices 1 to 3, were amplified by PCR. Full-length library molecules were generated by overlap extension PCR (oePCR), in which the nonrandomized region was amplified using PAdelFc as the template sequence.
[0120] Cloning of PA12 and PA13 was performed using randomized oligonucleotides (ELLA Biotech). The PAdelFc sequence served as a template. Full-length PA12 was generated by oePCR of one fragment containing helix 1 and randomized helix 2 and another fragment containing randomized helix 3. The coding region of PA13 was obtained in one PCR step using randomized oligonucleotides and the PAdelFc sequence as a template.
[0121] All generated library PCR products were ligated into a modified pCD87SA phagemid (herein referred to as pCD33-OmpA) using standard methods known to those skilled in the art. The pCD33-OmpA phagemid contains the OmpA leader sequence and a direct fusion to CT-pIII. An aliquot of the ligation mixture was used to electroporate E. coli strain SS320 (Lucigen). Established genetic recombination methods known to those skilled in the art.
[0122] Initial selection by TAT phage display The naive library was enriched against the target using phage display as a selection system. The phagemid pCD33-OmpA carrying the library was used to transform SS320 competent bacterial cells (Lucigene), followed by phage amplification and purification using standard methods known to those skilled in the art. For selection, the target protein was immobilized as an Fc fusion of the target on Dynabeads® Protein A or Dynabeads® Protein G. The concentration of target during phage incubation was reduced from 200 nM (1st round) to 100 nM (2nd round) and 50 nM (3rd round). The target-phage complex was magnetically separated from the supernatant and washed several times. Phage bound to the target were eluted with trypsin. To remove Fc-binding variants from the phage library, phage preselection using immobilized Fc fragment of IgG1 (Athens Research & Technology) was performed before the second and third rounds. To identify target-specific phage pools, eluted and reamplified phages from each round of selection were analyzed by phage pool ELISA. Target-Fc (2.5 μg / ml) and Fc fragment of IgG1 (2.5 μg / ml) were used to coat wells of a medium-binding microtiter plate (Greiner Bio-One), respectively. Bound phages were detected using HRP-conjugated anti-M13 antibody (GE Healthcare).
[0123] Cloning of target-binding phage pools into expression vectors Selected pools that showed specific binding to the target in the phage pool ELISA were amplified by PCR according to methods known in the art, digested with appropriate restriction nucleases, and ligated into a derivative of the expression vector pET-28a (Merck, Germany) containing Strep-TagII (IBA GmbH).
[0124] Single colony hit analysis Kanamycin-resistant single colonies were cultured after transformation of BL21(DE3) cells (Merck, Germany). The target-binding modified scaffold variants were expressed by culturing in 384-well plates (Greiner Bio-One) using autoinduction medium (Studier, 2005, Protein Expr. Purif. 41(1):207-234). Cells were harvested and subsequently lysed chemically or enzymatically with BugBuster reagent (Novagen) and mechanically by freeze-thaw cycles, respectively. After centrifugation, the resulting supernatants were screened by ELISA using immobilized targets on Hybind 384 ELISA microtiter plates (Greiner Bio-One). Bound proteins were detected by Strep-Tactin® HRP conjugate (IBA GmbH) in combination with TMB-Plus substrate (Biotrend, Germany). The reaction was stopped by adding 0.2 M H2SO4 solution, and measurements were taken at 450 nm and 620 nm in a plate reader.
[0125] Maturity selection and analysis Two rounds of panning were performed for affinity maturation. The first and second rounds used Fc fusions of the targets at concentrations of 50 nM and 5 nM, respectively. For both rounds, a preselection was performed using the Fc fragment of IgG1. Phage pool ELISA was performed to analyze these matured and selected pools for specific target binding, and subsequently positive pools were cloned into the expression vector pET-28a and hit ELISA was performed as described herein.
Claims
1. A polypeptide having at least 90% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 1-15 and 23-30, said polypeptide comprising (a) comprising an aspartic acid (D) at position 13 of SEQ ID NOs: 1-15 and 23-30; and (b) comprising an arginine (R) at position 31 of SEQ ID NOs: 1-15 and 23-30; A polypeptide, wherein the polypeptide has a triple helical structure, and wherein the polypeptide has no detectable binding affinity for an immunoglobulin Fc domain as measured by surface plasmon resonance (SPR).
2. The polypeptide of claim 1, further comprising serine (S) at one or more of positions 10, 14, and 35 of SEQ ID NOs: 1 to 15 and 23 to 30.
3. A fusion protein comprising the polypeptide according to any one of claims 1 to 2.
4. A method for producing a polypeptide according to any one of claims 1 to 2 having binding affinity for a target protein, said method comprising the steps of: (a) providing one or more polypeptides according to any one of claims 1 to 2, (b) contacting a target protein with one or more polypeptides of (a); (c) identifying a complex comprising the polypeptide according to any one of claims 1 to 2 bound to the target protein; (d) obtaining a polypeptide according to any one of claims 1 to 2 capable of binding to the target protein. A method comprising:
5. A composition comprising a polypeptide having binding affinity for a target protein, the polypeptide being obtained by any one of claims 1 to 2, or the fusion protein being obtained by the method ...
6. The composition of claim 5 for use as a pharmaceutical, diagnostic and / or prognostic agent.
7. A polypeptide prepared according to the method of claim 4.
8. A polynucleotide encoding the polypeptide according to any one of claims 1 to 2 and 7, or the fusion protein according to claim 3.
Citation Information
Patent Citations
Alkali-stable immunoglobulin-binding protein
JP2019531055A
Protein a mutant protein having reduced affinity in acidic region, and antibody capture agent
WO2012165544A1
ANTIBODY-BINDING PROTEIN HAVING REDUCED ANTIBODY-BINDING CAPACITY IN ACIDIC pH REGIONS
WO2017014257A1
